The MAH emphasizes that as with all vaccines and any medicinal product, such reactions or side effects may occur after administration of Covid-19 vaccines. According to the reports, vaccines developed by Pfizer / BioNTech and Moderna tend to have more severe side effects after the second dose of the vaccine. In contrast, for AstraZeneca, they tend to be more pronounced after the first dose. For all vaccines, side effects occur most often in the first few days after vaccination, last for a few days and then disappear rapidly. They are usually less pronounced in the elderly.
–
The MAH reminds that if, after receiving a dose of the vaccine, expected but severe or other reactions of the body, which significantly reduce the ability to work, are observed, a doctor should be consulted, who may decide to award a certificate of incapacity for work.
–
In this regard, Saeima deputy Vitalijs Orlovs (S) also previously indicated that on March 5, his acquaintance had been vaccinated with the “ABV5300” series vaccine. The vaccinators arrived on a trip to a particular company around 2 pm and on the same day the vaccination of the company’s employees took place later.
–
The next day, March 6, a person of retirement age, who had received the vaccine of the mentioned series, got worse with his health, his health also deteriorated on Sunday, March 7, and on Monday, March 8, his deputy’s acquaintance passed away, Orlov said.
–
The politician states that he understands that this case is about a 70-year-old person who has suffered from some diseases. At one time, an eternal acquaintance was active in his work, the parliamentarian drew attention.
–
The deputy emphasized that a person of retirement age had been vaccinated with the vaccine of this series “ABV5300”, about which on March 9 the state representatives informed that the use of vaccines of this series is temporarily suspended.
–
As reported, on March 9, information was received that, as an additional precaution, the Health Inspectorate (MA) and the MAH had temporarily suspended one vaccine. Use of the AstraZeneca single series. The MA and the MAH have been informed that the Austrian national competent pharmacovigilance authority has suspended the use of one batch of Covid-19 vaccine developed by AstraZeneca under the serial number “ABV5300”.
–
The deputy explained that according to the information available to him on the guidelines of the state authorities, the possible connection of a person’s death with the received vaccine could be assessed or both cases could be related if the person’s death occurred two days after vaccination. In this case, the person’s death occurred about the third day after receiving the vaccine, the politician said.
–
Orlov plans to write to the Minister of Health Daniels Pavļutas (AP) to ask when exactly Latvia received a warning from Austria about the possible risk of using the “ABV5300” series. The deputy wants to find out whether the relevant information would have been available to Latvia before March 9.
–
The politician points out that it is necessary to investigate this case in order to understand whether it is related or not to the use of the specific vaccine of the “ABV5300” series. Mr Orlov emphasized that he was not to blame for the vaccination process as such. At the same time, it must be clear how the vaccination process, such as the “road map”, is organized, the deputy pointed out.
–
It has already been reported that the ESA Safety Committee (PRAC) considers that the expected benefits of the vaccine still outweighs its risks and that the vaccine can be continued while thromboembolic events are being investigated. The ESA Safety Committee is already investigating all cases of thromboembolism and related events following vaccination with Covid-19 AstraZeneca.
–
The number of thromboembolic events in vaccinated individuals is not higher than in the general population. By March 10, 2021, 30 cases of thromboembolism had been reported per five million people who had received the Covid-19 vaccine “AstraZeneca” in the countries of the European Economic Area.
— .
